Economic implications of long-acting opioid switching

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.447, 2004-01, pp. : 13-13

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Switching from oral antipsychotics to long-acting risperidone

By  

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Long-Acting Opioid-Agonists in the Treatment of Heroin Addiction: Why Should We Call Them “Substitution”?

By Gerra G.   Maremmani I.   Capovani B.   Somaini L.   Berterame S.   Tomas-Rossello J.   Saenz E.   Busse A.   Kleber H.  

Substance Use & Misuse, Vol. 44, Iss. 5, 2009-04 ,pp. : 663-671

Informa Healthcare

Access to resources Recommend Favorite

Long-Acting Isosorbide Mononitrate

By Prakash A.   Markham A.  

Drugs, Vol. 57, Iss. 1, 1999-01 ,pp. : 93-99

Adis International

Access to resources Recommend Favorite

Long-Acting Antipsychotic Medications

By  

Current Drug Targets, Vol. 13, Iss. 4, 2012-04 ,pp. : 555-560

Bentham Science Publishers

Access to resources Recommend Favorite

Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable

By Rosa Fernanda  

Clinical Drug Investigation, Vol. 32, Iss. 4, 2012-04 ,pp. : 267-279

Adis International

Access to resources Recommend Favorite